A related study by Widjaja et al. (2022) similarly shows that treatment with anti-IL-11 and angiotensin-converting enzyme inhibitors (ACEi) synergistically improved clinical, molecular, and histopathological biomarkers of kidney disease and extended lifespan in a mouse model of Alport syndrome, a genetic condition that affects hearing, vision, and the glomerular basement membrane and can cause CKD [53]. This evidence concerns the gene IL11 and kidney disorder.